The Hutchmed-originated savolitinib moves towards its first US approval.

OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.

The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.

Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.

The group reports responses with its CD123-targeting ADC, but cash is running short.